2021 Annual Business Report

Our Financials & Outlook

Financials & Outlook

DEAR SHAREHOLDERS & INVESTORS

We aim to stand strong, through 2022 and beyond.

Financials & Outlook

Our Key Figures 2021

The 2021 financial results are marked by unprecedented R&D progress and our successful Nasdaq listing.

 

Shareholder structure (January 2021)

Shareholder structure
Our capital strategy

Our capital strategy

Our capital strategy is a combination of non-dilutive funding sources and equity capital to finance the development of the Company’s vaccine candidates.

Financials & Outlook

2022 Outlook

In 2022, Valneva expects to continue investing strongly in its R&D programs and increase vaccine sales, subject to regulatory approval of VLA2001.

2020-financial-reports-small.jpg

Valneva’s financial reports

Quote Financials

PETER BÜHLERChief Financial Officer